Commonwealth of Pennsylvania Public School Empls Retrmt SYS Sells 1,633 Shares of Moderna, Inc. (NASDAQ:MRNA)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS trimmed its position in Moderna, Inc. (NASDAQ:MRNA) by 2.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 72,005 shares of the company’s stock after selling 1,633 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Moderna were worth $2,994,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of MRNA. Wilmington Savings Fund Society FSB increased its holdings in shares of Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after acquiring an additional 587 shares in the last quarter. Compass Planning Associates Inc acquired a new position in shares of Moderna in the 4th quarter valued at approximately $37,000. Venturi Wealth Management LLC grew its position in shares of Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after purchasing an additional 664 shares during the period. MassMutual Private Wealth & Trust FSB raised its holdings in Moderna by 58.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after buying an additional 389 shares during the period. Finally, Blue Trust Inc. lifted its stake in Moderna by 53.1% in the fourth quarter. Blue Trust Inc. now owns 1,119 shares of the company’s stock valued at $47,000 after buying an additional 388 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Wall Street Analyst Weigh In

MRNA has been the subject of several research reports. Barclays downgraded shares of Moderna from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $111.00 to $45.00 in a research report on Tuesday, February 18th. Morgan Stanley dropped their price target on Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 15th. JPMorgan Chase & Co. reduced their price objective on Moderna from $40.00 to $33.00 and set an “underweight” rating for the company in a research report on Friday. Argus lowered Moderna from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Finally, The Goldman Sachs Group cut shares of Moderna from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $99.00 to $51.00 in a research note on Wednesday, January 29th. Four equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $59.00.

Moderna Price Performance

NASDAQ:MRNA opened at $34.17 on Tuesday. The company has a market cap of $13.21 billion, a P/E ratio of -3.68 and a beta of 1.86. The firm’s fifty day moving average price is $34.89 and its two-hundred day moving average price is $45.39. Moderna, Inc. has a one year low of $29.25 and a one year high of $170.47.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.